• Volume • • Electronic publication date:

Meningococcal Surveillance Australia
Reporting period 1 April to 30 June 2024

Monica M Lahra, Sonya Natasha Hutabarat, Tiffany R Hogan for the National Neisseria Network

The reference laboratories of the National Neisseria Network, Australia report data on invasive meningococcal disease (IMD) cases confirmed by culture and/or molecular techniques for the Australian Meningococcal Surveillance Programme (AMSP). Culture-positive cases and molecular-based diagnoses are defined as IMD by the Communicable Diseases Network Australia National Guidelines for Public Health Units.1 Data contained in the quarterly reports are restricted to a description of the number of cases by jurisdiction and serogroup, when known, and expanded in 2024 to include antimicrobial resistance data for ceftriaxone, penicillin, ciprofloxacin and rifampicin. Some minor corrections to data in Table 1 may be made in subsequent reports if additional data are received.

In the second quarter of 2024, IMD notifications in Australia were lower than in the corresponding period of 2023 (Table 1).2 Notably, the predominance of *N. meningitidis* serogroup B (MenB) IMD reported in 20223 has continued, accounting for 87% of notifications (27/31) in the second quarter of 2024. In contrast, between 2019 and 2021, the proportion of IMD attributable to MenB was 50–62%.4 There have not been any MenA IMD cases reported in Australia for many years and there were no MenC IMD cases reported in this quarter. Antimicrobial susceptibility testing data on the 22 IMD diagnosed by culture detected four penicillin-resistant isolates from Queensland (two MenB), Victoria (one MenB) and Western Australia (one MenW); all isolates were susceptible to ceftriaxone, ciprofloxacin and rifampicin. A full analysis of laboratory-confirmed cases of IMD in each calendar year is contained in the AMSP annual report published in *Communicable Diseases Intelligence*.

Table 1: Number of laboratory confirmations of invasive meningococcal disease, Australia, 1 April to 30 June 2024, by serogroup and state or territory

| Jurisdiction | Year | Serogroup |
| --- | --- | --- |
| B | W | Y | NDa | All |
| Q2 | ytdb | Q2 | ytd | Q2 | ytd | Q2 | ytd | Q2 | ytd |
| Australian Capital Territory | **2024** | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| **2023** | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| New South Wales | **2024** | 8 | 11 | 0 | 0 | 0 | 0 | 0 | 0 | 8 | 11 |
| **2023** | 9 | 15 | 2 | 2 | 1 | 2 | 0 | 0 | 12 | 19 |
| Northern Territory | **2024** | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| **2023** | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Queensland | **2024** | 7 | 12 | 0 | 0 | 0 | 1 | 0 | 1 | 7 | 14 |
| **2023** | 11 | 18 | 0 | 0 | 1 | 1 | 1 | 1 | 13 | 20 |
| South Australia | **2024** | 4 | 10 | 0 | 0 | 0 | 1 | 0 | 0 | 4 | 11 |
| **2023** | 8 | 10 | 1 | 1 | 0 | 0 | 0 | 0 | 9 | 11 |
| Tasmania | **2024** | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| **2023** | 0 | 2 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 3 |
| Victoria | **2024** | 4 | 6 | 0 | 0 | 3 | 3 | 0 | 1 | 7 | 10 |
| **2023** | 3 | 6 | 0 | 1 | 0 | 0 | 0 | 0 | 2 | 3 |
| Western Australia | **2024** | 3 | 3 | 1 | 2 | 0 | 0 | 0 | 0 | 4 | 5 |
| **2023** | 1 | 2 | 0 | 0 | 1 | 1 | 0 | 0 | 2 | 3 |
| **Australia** | **2024** | **27** | **43** | **1** | **2** | **3** | **5** | **0** | **2** | **31** | **52** |
| **2023** | **32** | **53** | **3** | **4** | **3** | **4** | **2** | **2** | **40** | **63** |

a ND: not determined.

b ytd: year to date, data from 1 April to 30 June 2024.

Author details

Monica M Lahra1,2

Sonya Natasha Hutabarat1

Tiffany R Hogan1

1. The World Health Organization Collaborating Centre for STI and AMR and Neisseria Reference Laboratory, NSW Health Pathology, Microbiology, Prince of Wales Hospital, Randwick, NSW, 2031, Australia
2. The School of Medical Sciences, Faculty of Medicine, University of New South Wales, Kensington, NSW, 2052, Australia

Corresponding author

Professor Monica M Lahra

World Health Organization Collaborating Centre for STI and AMR and Neisseria Reference Laboratory, Microbiology Department, NSW Health Pathology, Prince of Wales Hospital, Randwick, NSW, 2031, Australia

Telephone: +61 2 9382 3678

Facsimile: +61 2 9382 3720

Email: monica.lahra@health.nsw.gov.au

# References

1. Australian Government Department of Health and Aged Care, Communicable Diseases Network Australia (CDNA). *Invasive Meningococcal Disease: CDNA National Guidelines for Public Health Units*. Canberra: Australian Government Department of Health and Aged Care; 4 July 2017. Available from: https://www.health.gov.au/sites/default/files/documents/2020/02/invasive-meningococcal-disease-cdna-national-guidelines-for-public-health-units.pdf.
2. Lahra MM, George RCR, van Hal SJ, Hogan TR. Australian Meningococcal Surveillance Programme Annual Report, 2023. *Commun Dis Intell (2018)*. 2024:48. doi: https://doi.org/10.33321/cdi2024.48.52.
3. Lahra MM, George RCR, van Hal SJ, Hogan TR. Australian Meningococcal Surveillance Programme Annual Report, 2022. *Commun Dis Intell (2018)*. 2023:47. doi: https://doi.org/10.33321/cdi.2023.47.44.
4. Lahra MM, George RCR, Hogan TR. Australian Meningococcal Surveillance Programme Annual Report, 2021. *Commun Dis Intell (2018)*. 2022:46. doi: https://doi.org/10.33321/cdi.2022.46.46.

About Communicable Diseases Intelligence

Communicable Diseases Intelligence (CDI) is a peer-reviewed scientific journal published by the Health Security & Emergency Management Division, Department of Health and Aged Care. The journal aims to disseminate information on the epidemiology, surveillance, prevention and control of communicable diseases of relevance to Australia.

© Commonwealth of Australia as represented by the Department of Health and Aged Care

ISSN: 2209-6051 Online

This journal is indexed by Index Medicus and Medline.

This publication is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Licence (CC BY-NC-ND) available from https://creativecommons.org/licenses/by-nc-nd/4.0/legalcode (Licence). You must read and understand the Licence before using any material from this publication.

Restrictions

The Licence does not cover, and there is no permission given for, use of any of the following material found in this publication (if any):

* the Commonwealth Coat of Arms (by way of information, the terms under which the Coat of Arms may be used can be found at www.pmc.gov.au/resources/commonwealth-coat-arms-information-and-guidelines);
* any logos (including the Department of Health and Aged Care’s logo) and trademarks;
* any photographs and images;
* any signatures; and
* any material belonging to third parties.

Disclaimer

Opinions expressed in *Communicable Diseases Intelligence* are those of the authors and not necessarily those of the Australian Government Department of Health and Aged Care or the Communicable Diseases Network Australia. Data may be subject to revision.

Enquiries

Enquiries regarding any other use of this publication should be addressed to the CDI Editor at: cdi.editor@health.gov.au

Communicable Diseases Network Australia

Communicable Diseases Intelligence contributes to the work of the Communicable Diseases Network Australia. www.health.gov.au/cdna

**Editor**: Christina Bareja • **Deputy Editor**: Simon Petrie • **Design and Production**: Lisa Thompson

**Editorial Advisory Board**: David Durrheim, Mark Ferson, Clare Huppatz, John Kaldor, Martyn Kirk and Meru Sheel

Contacts

CDI is produced by:

Health Security & Emergency Management Division, Australian Government Department of Health and Aged Care,
GPO Box 9848, (MDP 6) CANBERRA ACT 2601

Website: [www.health.gov.au/cdi](http://www.health.gov.au/cdi)

Email: cdi.editor@health.gov.au

Submit an Article

You are invited to submit your next communicable disease related article to the *Communicable Diseases Intelligence* (CDI) for consideration. More information regarding CDI can be found at: www.health.gov.au/cdi.

Further enquiries should be directed to: cdi.editor@health.gov.au